Previous 10 | Next 10 |
2024-05-27 11:34:31 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips With the S&P 500 sitting just a few points below setting a new all-time high, the bull market that began in 2022 is still snorting. Although a correction or even a bear market will even...
2024-05-24 21:15:02 ET Stephens analyst issues BUY recommendation for GH on May 24, 2024 05:00PM ET. The previous analyst recommendation was Buy. GH was trading at $25.52 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst rec...
2024-05-24 21:15:01 ET Piper Sandler analyst issues UNDERPERFORM recommendation for GH on May 24, 2024 05:00PM ET. The previous analyst recommendation was Underperform. GH was trading at $25.52 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-05-24 09:25:08 ET More on Guardant Health Guardant Health, Inc. (GH) Q1 2024 Earnings Call Transcript Guardant Health: Shield Launch Could Drive Multiple Expansion Guardant Health colorectal cancer screening test endorsed by FDA advisors Guardant shares ...
The advisory committee offers valuable non-binding recommendations for the FDA Blood test offers a convenient non-invasive screening option that overcomes barriers associated with current non-invasive screening tests Shield remains on track to become the first FDA-approved blood t...
2024-05-23 17:05:39 ET More on Guardant Health Guardant Health slips as FDA comments on cancer screening test Guardant Health: Shield Launch Could Drive Multiple Expansion Guardant Health, Inc. (GH) Q1 2024 Earnings Call Transcript Seeking Alpha’s Quan...
2024-05-23 08:39:07 ET More on Guardant Health Guardant Health, Inc. (GH) Q1 2024 Earnings Call Transcript Guardant Health: Shield Launch Could Drive Multiple Expansion Guardant Health slips as FDA comments on cancer screening test Guardant Health Non-GAAP EP...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Nasdaq has temporarily halted trading of the company's stock. The Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration (FDA) Medical Devices Advisory Committee will meet to...
2024-05-21 11:05:08 ET More on Guardant Health Guardant Health, Inc. (GH) Q1 2024 Earnings Call Transcript Guardant Health: Shield Launch Could Drive Multiple Expansion Guardant Health, Inc. (GH) Q4 2023 Earnings Call Transcript Guardant Health Non-GAAP EPS o...
Blood-based test for comprehensive genomic profiling of solid cancers meets requirements under stricter EU In Vitro Diagnostic Regulation IVDR certification from TÜV SÜD enables broader adoption of guideline-recommended genomic profiling to inform optimal therapy selection for p...
News, Short Squeeze, Breakout and More Instantly...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Ti...
Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity Upgraded test covered ...
2024-07-21 23:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...